Oncocyte Corp Files 8-K on Financials
Ticker: IMDX · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1642380
Sentiment: neutral
Topics: financial-results, 8-k
TL;DR
Oncocyte Corp dropped an 8-K on Nov 12th covering financials. Check it out.
AI Summary
On November 12, 2024, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the report being as of November 12, 2024. Oncocyte Corporation is incorporated in California and its principal executive offices are located in Irvine, California.
Why It Matters
This 8-K filing provides an update on Oncocyte Corporation's financial condition and operational results, which is crucial information for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- November 12, 2024 (date) — Date of Report
- California (location) — State of Incorporation
- Irvine, California (location) — Address of Principal Executive Offices
- 949-409-7600 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Oncocyte Corporation, and it includes Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on November 12, 2024.
Where is Oncocyte Corporation's principal executive office located?
Oncocyte Corporation's principal executive office is located at 15 Cushing, Irvine, California 92618.
In which state is Oncocyte Corporation incorporated?
Oncocyte Corporation is incorporated in California.
What is the SIC code for Oncocyte Corporation?
The Standard Industrial Classification (SIC) code for Oncocyte Corporation is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-11-12 16:05:19
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 390KB
- 0001493152-24-044741.txt ( ) — 625KB
- ocx-20241112.xsd (EX-101.SCH) — 3KB
- ocx-20241112_lab.xml (EX-101.LAB) — 33KB
- ocx-20241112_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: November 12, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer